Association Between MTHFR C677T Polymorphism and Methotrexate Treatment Outcome in Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis.

@article{Shao2017AssociationBM,
  title={Association Between MTHFR C677T Polymorphism and Methotrexate Treatment Outcome in Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis.},
  author={Wenjing Shao and Yi Yuan and Yuying Li},
  journal={Genetic testing and molecular biomarkers},
  year={2017},
  volume={21 5},
  pages={
          275-285
        }
}
PURPOSE Methotrexate (MTX) is one of the most widely used disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis (RA). However, its efficacy in RA patients is variable and unpredictable. Methylene tetrahydrofolate reductase (MTHFR) is an important enzyme in the MTX pathway and is involved in folate metabolism and DNA synthesis. Several studies have examined the association between the MTHFR C677T polymorphism and MTX toxicity and efficacy in RA, but their conclusions… Expand
Are gene polymorphisms related to adverse events of methotrexate in patients with rheumatoid arthritis? A retrospective cohort study based on an updated meta-analysis
TLDR
Evidence-based results suggest that the MTHFR 677C>, ATIC 347C>G(rs2372536), RFC-1 80G>A (rs1051266), ABCB1 3435C>T(rs1045642) polymorphisms are associated with MTX-related toxicity. Expand
Association of MTHFR and RFC1 gene polymorphisms with methotrexate efficacy and toxicity in Chinese Han patients with rheumatoid arthritis
TLDR
In Chinese Han patients with RA, the MTHFR C667T SNP may correlate with MTX toxicity, whereas the RFC-1 A80G SNP may correlation withMTX efficacy rather than toxicity. Expand
Associations between gene polymorphisms and treatment outcomes of methotrexate in patients with juvenile idiopathic arthritis.
TLDR
C677T (rs1801133) polymorphism in MTHFR predicts nonresponse and/or adverse effects of MTX treatment in JIA patients. Expand
Association of genetic polymorphisms on methotrexate toxicity in patients with rheumatoid arthritis
TLDR
Pharmacogenomic analysis of gene polymorphisms in the MTX metabolic pathway, such as MTHFR, MTHFD1, MTR, and ABCC2, may facilitate decision-making in relation to MTX treatment toxicity among RA patients. Expand
Association between ABCB1 C3435T polymorphism and methotrexate treatment outcomes in rheumatoid arthritis patients: a meta-analysis.
TLDR
The results demonstrated that the ABCB1 gene C3435T polymorphism might be a reliable predictor of response to methotrexate in rheumatoid arthritis patients, however, well-designed, multicenter and large-scale prospective studies are required to further confirm the validity of the results. Expand
Genetic markers in methotrexate treatments
TLDR
It is concluded that only gene polymorphisms MTHFR rs1801133, SLC19A1 rs1051266, and TYMS rs34743033 could influence clinical decision-making on MTX toxicity and efficacy. Expand
Genetic Polymorphisms Associated with Rheumatoid Arthritis Development and Antirheumatic Therapy Response
TLDR
The review has two purposes: to summarise the data on RA candidate genes and the increased disease risk associated with these alleles in various populations and to describe how the genetic variants can be used in the selection of drugs for the treatment of RA. Expand
Folate pathway genetic polymorphisms modulate methotrexate-induced toxicity in childhood acute lymphoblastic leukemia
TLDR
Genetic polymorphisms of the folate pathway may modulate MTX-induced toxicity in childhood ALL and may also modulate hematological toxicities in children with ALL. Expand
The thymidylate synthase enhancer region (TSER) polymorphism increases the risk of thymic lymphoid hyperplasia in patients with Myasthenia Gravis.
TLDR
The present study suggests that the TYMS TSER 3R allele increases the risk of thymic lymphoid hyperplasia in AChR+ MG patients. Expand
Expression of the C677T Polymorphism of the 5, 10-Methylenetetrahydrofolate Reductase (MTHFR) Gene in Patients with Carotid Artery Atherosclerosis
TLDR
Logistic regression analysis showed that SBP, TC, LDL-C, and the C667T MTHFR gene polymorphism were risk factors for carotid artery atherosclerosis. Expand
...
1
2
...

References

SHOWING 1-10 OF 67 REFERENCES
Influence of MTHFR C677T polymorphism on methotrexate monotherapy discontinuation in rheumatoid arthritis patients: results from the GAPAID European project.
TLDR
It is demonstrated that the C677T polymorphism in the MTHFR gene is involved in MTX monotherapy discontinuation in a multicentre European patient cohort, confirming previous results. Expand
Association of the MTHFR C677T and A1298C polymorphisms with methotrexate toxicity in rheumatoid arthritis: a meta-analysis
TLDR
The results of the meta-analysis suggest that the MTHFR C677T and A1298C polymorphisms are associated with MTX toxicity in RA patients. Expand
The C677T polymorphism in the MTHFR gene is associated with the toxicity of methotrexate in a Spanish rheumatoid arthritis population
TLDR
It is demonstrated that the C677T polymorphism in the MTHFR gene is associated with MTX toxicity in a Spanish RA population. Expand
Genetic Determinants of Methotrexate Toxicity in Tunisian Patients with Rheumatoid Arthritis: A Study of Polymorphisms Involved in the MTX Metabolic Pathway
TLDR
It is demonstrated that the C677T polymorphism in the MTHFR gene is associated with MTX toxicity in Tunisian RA patients and the TYMS 2R/3R polymorphism had a protective effect against overallMTX toxicity. Expand
The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients
TLDR
Data show greater ability of 677CC–1298CC and 677TT– 1298AA genotypes to respond to MTX treatment, which is an intriguing finding, because these double-mutated homozygotes are known for their low MTHFR-specific activity. Expand
677C>T and 1298A>C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis.
TLDR
The results of this study suggest that the MTHFR 677T and 1298C alleles may be associated with an increased rate of RA remission in patients treated with MTX receiving high doses of folic acid supplementation. Expand
Pharmacogenetic polymorphisms contributing to toxicity induced by methotrexate in the southern Spanish population with rheumatoid arthritis.
TLDR
The presence of the MTHFR C677T and ABCB1 C3435T SNPs contribute to MTX toxicity in patients with RA, and observations contribute to a rapidly-growing knowledge base on the pharmacogenetics of RA and personalized medicine. Expand
MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms
TLDR
The available evidence suggests that the MTHFR C677T and A1298C gene polymorphisms are not reliable predictors of response to MTX treatment in RA patients. Expand
MTHFR functional genetic variation and methotrexate treatment response in rheumatoid arthritis: a meta-analysis.
TLDR
MTHFR SNPsrs1801131 and rs1801133 were not associated with response to MTX in the YEAR cohort, nor did they affect the probability of achieving a low disease activity state, and a meta-analysis of comparable studies found no association with these SNPs. Expand
A single nucleotide polymorphism of reduced folate carrier 1 predicts methotrexate efficacy in Japanese patients with rheumatoid arthritis.
TLDR
The results of this study suggest that the RFC1 G80A polymorphism may be a useful marker for predicting MTX efficacy in Japanese patients with RA. Expand
...
1
2
3
4
5
...